Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $28.24
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 18, 26 |
| BTIG |
| maintain |
| Buy |
| Buy |
| Sep 18, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Aug 19, 26 | Truist Securities | maintain | Buy | Buy |
| Aug 19, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 4, 26 | JP Morgan | maintain | Overweight | Overweight |
| May 20, 26 | UBS | maintain | Buy | Buy |
| May 20, 26 | Truist Securities | maintain | Buy | Buy |
| Feb 25, 26 | Evercore ISI Group | maintain | Outperform | Outperform |
| Feb 19, 26 | Evercore ISI Group | maintain | Outperform | Outperform |
TTM vs. 5-year historical average (annual ratios)
| Metric | AS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 29.1x | 25.3x · sector 73.6x | Discount |
| Forward P/E (FY26E) | 21.7x | EPS est. 1.30 | Discount |
| Price / Book | 2.4x | 9.9x | Discount |
| Price / Sales | 2.2x | 2.3x | In line |
| EV / EBITDA | 12.7x | 29.7x | Discount |
| Return on equity | 8.7% | — | Weak |
| Gross margin | 59.8% | 52.9% | In line |
| Debt / Equity | 0.16 | 8.06 | Conservative |
| Piotroski / Altman Z | 8/9 | Z 4.10 | Safe zone |
Discounted cash flow model
685 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 45.61 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 55.20 | Oscillator | Neutral |
| Williams %R (14) | -62.59 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.20 (Hist 0.15) | Oscillator | Strong Buy |
| Average Directional Index (14) | 20.44 (+DI 24.3 / -DI 31.4) | Trend | Sell |
| EMA 20 | 28.78 | MA | Sell |
| SMA 20 | 28.40 | MA | Sell |
| EMA 50 | 29.52 | MA | Strong Sell |
| SMA 50 | 29.02 | MA | Sell |
| SMA 200 | 33.93 | MA | Strong Sell |
Stock news · updated daily
Investors interested in stocks from the Leisure and Recreation Products sector have probably already heard of Academy Sports and Outdoors, Inc. (ASO) and Amer Sports, Inc. (AS). But which of these two companies is the best option for those looking for undervalued stocks?
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
The disposition involved ~117,000 shares for a total value of $3.1 million. Traded shares represented 78% of the equity stake held directly before the filing.
New SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw
AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
Lakeland Industries (NASDAQ: LAKE - Get Free Report) and Amer Sports (NYSE: AS - Get Free Report) are both consumer discretionary companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends. Profitability This table compares Lakeland Industries and
Amer Sports, Inc. (AS) Analyst/Investor Day Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 18, 2026 | 0.11 | 0.22 | Beat 108.3% | $1.63B |
| May 19, 2026 | 0.31 | 0.38 | Beat 24.1% | $1.95B |
| Feb 24, 2026 | 0.28 | 0.31 | Beat 11.0% | $2.10B |
| Nov 18, 2025 | 0.25 | 0.33 | Beat 31.0% | $1.76B |
| Aug 19, 2025 | 0.02 | 0.06 | Beat 143.2% | $1.24B |
| May 20, 2025 | 0.15 | 0.27 | Beat 75.0% | $1.47B |
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Oct 16, 2026 | 2026-10-16 16:17:13 | View |
| 4 | Sep 17, 2026 | 2026-09-17 07:23:32 | View |
| 6-K | Sep 16, 2026 | 2026-09-16 16:17:49 | View |
| 144 | Sep 15, 2026 | 2026-09-15 19:05:05 | View |
| 4 | Sep 2, 2026 | 2026-09-02 19:09:22 | View |
| 144 | Sep 2, 2026 | 2026-09-02 19:04:56 | View |
| SC 13D/A | Aug 24, 2026 | 2026-08-24 06:03:07 | View |
| 6-K | Aug 18, 2026 | 2026-08-18 09:19:58 | View |
| 6-K | Aug 18, 2026 | 2026-08-17 19:20:07 | View |
| 4 | Jun 5, 2026 | 2026-06-05 07:26:45 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 15, 26 | Chen Wen-Chang (Victor) | officer: Chief Strategy Officer | M-Exempt | 402,495 @ $7.68 | $3.09M |
| Sep 15, 26 | Chen Wen-Chang (Victor) | officer: Chief Strategy Officer | S-Sale | 117,461 @ $26.60 | $3.12M |
| Sep 15, 26 | Chen Wen-Chang (Victor) | officer: Chief Strategy Officer | M-Exempt | 402,495 @ $7.68 | $3.09M |
| Sep 1, 26 | Page Andrew E | officer: Chief Financial Officer | M-Exempt | 4,514 | — |
| Sep 1, 26 | Page Andrew E | officer: Chief Financial Officer | M-Exempt | 4,514 | — |
| Sep 2, 26 | Page Andrew E | officer: Chief Financial Officer | S-Sale | 2,022 @ $28.63 | $57.89K |
| Jun 3, 26 | Zheng Jie (James) | director, officer: Chief Executive Officer | M-Exempt | 500,000 @ $7.68 | $3.84M |
| Jun 3, 26 | Zheng Jie (James) | director, officer: Chief Executive Officer | S-Sale | 500,000 @ $34.42 | $17.21M |